This article is more than 5 years old. Information may no longer be current.

Wills Eye selected as site for trial of Stargardt's macular dystrophy treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MARLBOROUGH, Mass. — Wills Eye Institute has been approved as a site for a phase 1/2 clinical trial for Stargardt's macular dystrophy, according to a news release from Advanced Cell Technology, the sponsor of the trial.

The prospective, open-label study will evaluate the subretinal transplantation of retinal pigment epithelial cells derived from human embryonic stem cells into patients with Stargardt's macular dystrophy.

The trial will include 12 participants assigned into four groups receiving ascending dosages.

"Our team is eagerly anticipating working with Dr. Carl Regillo, a renowned retinal surgeon and director of clinical retina research at Wills Eye Institute, as well as a professor of ophthalmology at Thomas Jefferson University, along with the rest of his team as we move forward with these ground-breaking trials," Gary Rabin, chairman and CEO of Advanced Cell Technology, said in the release.

Wills Eye was recently selected as a site for Advanced Cell Technology's trial of a dry age-related macular degeneration therapy using embryonic stem cells.